Aibotics Inc. (AIBT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.71: the stock has moved about 71% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAibotics Inc. (AIBT) trades at $0.0022. Aibotics Inc. focuses on psychedelic methodologies for mental health treatment in the United States. The company researches treatments for palliative care, depression, and anxiety, operating in the biotechnology sector. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for AIBT: AIBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Aibotics Inc. (AIBT) Healthcare & Pipeline Overview
Aibotics Inc. is a biotechnology company focused on psychedelic methodologies for treating mental health issues such as palliative care, depression, and anxiety in the United States. Formerly Mycotopia Therapies, the company rebranded in February 2025 and is based in Miami, Florida, operating with a negative profit margin.
What Is the Investment Thesis for AIBT?
Investing in Aibotics Inc. presents a high-risk, high-reward opportunity in the emerging field of psychedelic medicine. The company's focus on developing treatments for mental health conditions such as palliative care, depression, and anxiety aligns with a growing recognition of the therapeutic potential of psychedelics. However, Aibotics operates in a highly regulated and competitive industry, and its financial performance is currently characterized by a negative profit margin of -314.5%. Key growth catalysts include the potential for regulatory approvals of psychedelic-assisted therapies and the expansion of clinical trials to demonstrate the efficacy of Aibotics' methodologies. The company's success will depend on its ability to navigate the complex regulatory landscape, secure funding for research and development, and establish strategic partnerships with healthcare providers and research institutions. The high beta of 1.71 indicates significant volatility, reflecting the speculative nature of the investment.
Based on FMP financials and quantitative analysis
AIBT Key Highlights
Aibotics Inc. operates in the biotechnology sector, focusing on psychedelic methodologies for mental health treatment.
- The company's research targets palliative care, depression, and anxiety, addressing significant unmet needs in mental healthcare.
- Aibotics Inc. rebranded from Mycotopia Therapies in February 2025, signaling a strategic shift.
- The company is based in Miami, Florida, positioning it within a growing hub for healthcare innovation.
- Aibotics Inc. has a negative profit margin of -314.5%, reflecting its early-stage development and investment in research.
Who Are AIBT's Competitors?
AIBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $358.07 | -0.20% | $38.3B | 96 5-pillar |
| DMRA Galecto, Inc. | $20.65 | +2.08% | $1.27B | 56 5-pillar |
| CGEM Cullinan Therapeutics, Inc. | $15.51 | +6.74% | $953M | 56 5-pillar |
| HITI High Tide Inc. | $2.63 | -1.50% | $231M | 38 5-pillar |
| LFMDP LifeMD, Inc. | $22.74 | -1.75% | $155M | — |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AIBT's Key Strengths?
Focus on the emerging field of psychedelic medicine.
- Proprietary psychedelic methodologies.
- Potential for innovative treatments for mental health disorders.
- Experienced leadership team.
What Are AIBT's Weaknesses?
Negative profit margin.
- Limited operating history.
- Dependence on regulatory approvals.
- High competition in the biotechnology industry.
What Are the Key Risks for AIBT?
Financial-distress signal — its Altman Z-Score of -46.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals for psychedelic-based therapies.
- Competition from established pharmaceutical companies and other biotech firms.
- Negative public perception of psychedelics and concerns about their safety and efficacy.
- Uncertainty surrounding the long-term effects of psychedelic therapies.
- Financial risks associated with operating in a highly regulated and capital-intensive industry.
What Are AIBT's Competitive Advantages?
- Proprietary psychedelic methodologies.
- Early mover advantage in the emerging field of psychedelic medicine.
- Focus on specific mental health conditions with unmet needs.
- Potential for intellectual property protection through patents and trade secrets.
What Does AIBT Do?
Aibotics Inc., formerly known as Mycotopia Therapies, is a biotechnology company dedicated to the research and development of psychedelic methodologies for treating mental health disorders. Founded with the vision of providing innovative solutions for conditions like palliative care, depression, and anxiety, the company officially changed its name to Aibotics Inc. in February 2025, signaling a strategic shift in its approach to mental health treatment. Based in Miami, Florida, Aibotics operates primarily within the United States, focusing on the burgeoning field of psychedelic-assisted therapy. The company's core activities revolve around studying the therapeutic potential of psychedelic compounds and developing methodologies for their safe and effective use in clinical settings. Aibotics aims to address the unmet needs of patients suffering from mental health conditions by pioneering novel treatment options that leverage the unique properties of psychedelics. While still in its early stages, Aibotics is actively engaged in research and development efforts to advance its pipeline of psychedelic-based therapies. The company's focus on palliative care, depression, and anxiety reflects a commitment to addressing some of the most pressing mental health challenges facing society today. As the regulatory landscape surrounding psychedelics evolves, Aibotics seeks to position itself as a leader in the development and commercialization of innovative treatments that can improve the lives of patients in need.
What Products and Services Does AIBT Offer?
- Studies psychedelics for mental health treatment.
- Develops psychedelic methodologies for palliative care.
- Creates psychedelic methodologies for depression.
- Creates psychedelic methodologies for anxiety.
- Researches novel therapies for mental health disorders.
- Aims to provide innovative solutions for mental health conditions.
- Focuses on the therapeutic potential of psychedelic compounds.
How Does AIBT Make Money?
- Research and development of psychedelic-based therapies.
- Conducting clinical trials to evaluate the efficacy of its methodologies.
- Seeking regulatory approvals for its therapies.
- Potential commercialization of approved therapies through partnerships or direct sales.
What Industry Does AIBT Operate In?
Aibotics Inc. operates within the rapidly evolving biotechnology industry, specifically targeting the emerging field of psychedelic medicine. The market for mental health treatments is substantial, with increasing recognition of the limitations of existing therapies and growing interest in alternative approaches. The competitive landscape includes companies like CKNTF (Cyknos Therapeutics Inc.) and MRVT (Murrieta Genomics Inc.), which are also exploring innovative solutions for healthcare challenges. The industry is characterized by high regulatory hurdles, significant research and development costs, and intense competition for funding and market share. As of 2026, the psychedelic medicine market is still nascent, but projections suggest substantial growth as regulatory barriers are reduced and clinical evidence accumulates.
Who Are AIBT's Key Customers?
- Patients suffering from palliative care needs.
- Patients suffering from depression.
- Patients suffering from anxiety.
- Healthcare providers seeking innovative treatment options.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Aibotics Inc. operates in the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Benjamin Kaplan. AIBT has traded publicly since 2006.
Key Financial Metrics
Return on equity for Aibotics Inc. stands at 55.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Aibotics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -46.30 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
3 transactions · 0 purchases, 0 sales, 3 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
AIBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
AIBT Latest News
No recent news available for AIBT.
AIBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AIBT.
Price Targets
Wall Street price target analysis for AIBT.
AIBT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AIBT; grades run from A+ (80-100) to F (below 30).
Leadership: Benjamin Kaplan
CEO
Benjamin Kaplan serves as the Chief Executive Officer of Aibotics Inc. His background includes experience in the healthcare and biotechnology sectors, with a focus on identifying and developing innovative therapies for unmet medical needs. Kaplan's expertise lies in strategic planning, business development, and capital raising. He has a proven track record of building and scaling companies in the healthcare industry.
Track Record: Since assuming the role of CEO, Benjamin Kaplan has focused on rebranding the company and shifting its strategic focus towards psychedelic methodologies. Key milestones under his leadership include initiating clinical trials and securing partnerships with research institutions. Kaplan's leadership is aimed at positioning Aibotics as a leader in the emerging field of psychedelic medicine.
AIBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aibotics Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies are not required to be SEC reporting companies.
- OTC Tier: OTC Other
- Limited regulatory oversight.
- Potential for fraud or manipulation.
- Lack of financial transparency.
- Limited liquidity.
- High price volatility.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company's focus on psychedelic methodologies for mental health treatment.
- Rebranding and strategic shift towards psychedelic medicine.
- Initiation of clinical trials.
- Partnerships with research institutions.
Common Questions About AIBT (Healthcare)
What do analysts say about AIBT stock?
As of March 16, 2026, there is limited analyst coverage of AIBT stock due to its OTC listing and early stage of development. Key valuation metrics such as P/E ratio (-0.09) and profit margin (-314.5%) reflect the company's current financial challenges.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Aibotics Inc. due to its OTC listing and early stage of development.
- Financial data is limited and may not be representative of future performance.
- The psychedelic medicine industry is subject to significant regulatory uncertainty.